Kingworld Medicines Group (HKSE:01110) ROCE % : 9.23% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Kingworld Medicines Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kingworld Medicines Group's annualized ROCE % for the quarter that ended in Dec. 2023 was 9.23%.

Kingworld Medicines Group ROCE % Historical Data

The historical data trend for Kingworld Medicines Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kingworld Medicines Group ROCE % Chart

Kingworld Medicines Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

12.35

12.65

11.46

10.42

13.09

Kingworld Medicines Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															8.99	13.16	7.56	17.63	9.23

Kingworld Medicines Group ROCE % Calculation

Kingworld Medicines Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	115.29	/	( ( (1410.816 - 604.97)	+	(1463.093 - 507.002) )	/ 2 )
	=	115.29	/	( (805.846	+	956.091)	/ 2 )
	=	115.29	/	880.9685
	=	13.09 %

Kingworld Medicines Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	83.762	/	( ( (1498.247 - 638.687)	+	(1463.093 - 507.002) )	/ 2 )
	=	83.762	/	( ( 859.56	+	956.091 )	/ 2 )
	=	83.762	/	907.8255
	=	9.23 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Kingworld Medicines Group (HKSE:01110) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kingworld Medicines Group ROCE % Related Terms

Thank you for viewing the detailed overview of Kingworld Medicines Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kingworld Medicines Group (HKSE:01110) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Kingworld Medicines Group Ltd (HKSE:01110) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

198 Daxin Road, 8th-9th Floor, Block A, Majialong Chuangxin Building, Nanshan District, Guangdong Province, Shenzhen, CHN, 518016

Website

https://www.kingworld.com.cn

Kingworld Medicines Group Ltd is engaged in Distribution sales of pharmaceutical and healthcare products such as branded imported pharmaceutical and healthcare products primarily in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices primarily carried out in the PRC. It derives the majority of its revenue from Distribution sales of pharmaceutical and healthcare products segment.

Kingworld Medicines Group (HKSE:01110) Headlines

No Headlines